2. Search Result
Search Result
Results for "

and myocardial infarction

" in MedChemExpress (MCE) Product Catalog:

160

Inhibitors & Agonists

1

Screening Libraries

2

Biochemical Assay Reagents

20

Peptides

6

Inhibitory Antibodies

19

Natural
Products

13

Isotope-Labeled Compounds

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108841
    Raleukin
    50+ Cited Publications

    Kineret; Anakinra

    		 Interleukin Related Inflammation/Immunology Cancer
    Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction .
    Raleukin
  • HY-141537
    ABR-238901
    5 Publications Verification

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial infarction (MI) research .
    ABR-238901
  • HY-17380
    (S)-Timolol maleate
    5 Publications Verification

    (S)-L-714,465 maleate; MK 950

    		 Adrenergic Receptor Cardiovascular Disease Neurological Disease Cancer
    (S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic β-adrenoceptor blocker. (S)-Timolol Maleate is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor. (S)-Timolol Maleate can be used for hypertension, angina pectoris and myocardial infarction .
    (S)-Timolol maleate
  • HY-16657
    TAPI-1
    10+ Cited Publications

    		 MMP NF-κB Apoptosis TNF Receptor Inflammation/Immunology Cancer
    TAPI-1 is a broad-spectrum MMP inhibitor and NF-κB p65 inhibitor that targets ADAM17/TACE, ADAM10 and other proteins. TAPI-1 reduces the proteolytic cleavage of membrane-bound TNF-α, decreases TNF-α levels, inhibits NF-κB pathway activation, and downregulates profibrotic markers. TAPI-1 reduces the proportion of proinflammatory immune cells, alleviates cardiac and airway fibrosis, and improves cardiac function after myocardial infarction. Meanwhile, TAPI-1 inhibits the viability, migration and invasion of esophageal squamous cell carcinoma cells, enhances the chemosensitivity of Cisplatin (HY-17394), induces apoptosis, and shows low toxicity to normal esophageal epithelial cells. TAPI-1 can be widely used in studies related to myocardial infarction-induced heart failure, severe traumatic tracheal stenosis, esophageal squamous cell carcinoma and other conditions .
    TAPI-1
  • HY-108865
    Alteplase

    Actilyse; Activase

    		 Ser/Thr Protease Cardiovascular Disease Cancer
    Alteplase (Actilyse; Activase), a tissue plasminogen activator prepared by recombination, is a thrombolytic agent that play important roles in acute ischemic stroke, pulmonary embolism, acute myocardial infarction, and occluded catheters .
    The product size below only indicate the effective content of Alteplase. The ratio of Alteplase effective content : total content = 1:46-1:50. The actual ratio depends on the batch.)
    Alteplase
  • HY-B1409
    Isosorbide dinitrate

    ISDN

    		 NO Synthase Cardiovascular Disease
    Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI) .
    Isosorbide dinitrate
  • HY-B0592
    Trandolapril

    RU44570

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
    Trandolapril
  • HY-B1770
    Sodium Iodide,99%

    		Environmental Pollutants Biochemical Assay Reagents Cardiovascular Disease Endocrinology
    Sodium Iodide is a compound composed of sodium ions and iodine ions. Sodium Iodide scavenges hydrogen peroxide. Sodium Iodide maintains the level of thyroid hormone T3 through its iodine component. Sodium Iodide protects tissues from oxidative damage and regulates thyroid homeostasis. Sodium Iodide relieves acute myocardial infarction .
    Sodium Iodide,99%
  • HY-134418
    NOTA

    		Radionuclide-Drug Conjugates (RDCs) Cardiovascular Disease Cancer
    NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools. NOTA also can be used for probe design and signal amplification via the multivalent effect. NOTA can be used in multiple myeloma, breast cancer, lymphoma and myocardial infarction research .
    NOTA
  • HY-111132
    JT010
    3 Publications Verification

    		 TRP Channel Cardiovascular Disease
    JT010 is a covalent and site-selective TRPA1 agonist. JT010 can be used in myocardial infarction research .
    JT010
  • HY-153999A
    Rondaptivon pegol sodium

    BT200 sodium

    		 Integrin Apoptosis Cardiovascular Disease Inflammation/Immunology
    Rondaptivon pegol (BT200) sodium is an aptamer targeting von Willebrand factor (VWF), with an EC50 of 33 nM in humans. Rondaptivon pegol sodium effectively alleviates acute myocardial ischemia-reperfusion injury in mice by inhibiting VWF activity, reducing microvascular obstruction, inflammatory responses and cardiomyocyte apoptosis (apoptosis). Rondaptivon pegol sodium inhibits the binding of VWF to platelet glycoprotein GPIb, thereby preventing arterial thrombosis in cynomolgus monkeys. Rondaptivon pegol sodium can be used in research related to arterial thrombosis, stroke, myocardial infarction and myocardial ischemia-reperfusion injury .
    Rondaptivon pegol sodium
  • HY-N0107
    Cyclovirobuxine D
    1 Publications Verification

    		 Apoptosis Autophagy mTOR Akt Cardiovascular Disease
    Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces autophagy and attenuates the phosphorylation of Akt and mTOR . Cyclovirobuxine D inhibits cell proliferation of gastric cancer cells through suppression of cell cycle progression and inducement of mitochondria-mediated apoptosis . Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction .
    Cyclovirobuxine D
  • HY-P10728
    B7-33

    		RXFP Receptor ERK Cardiovascular Disease Inflammation/Immunology
    B7-33 is a single-chain relaxin mimetic and a selective relaxin receptor 1 (RXFP1) agonist. B7-33 phosphorylates ERK1/2 without inducing activation of the cAMP signaling pathway. B7-33 exhibits anti-fibrotic and cardioprotective activities. B7-33 can be used in the research of vascular diseases such as cardiomyopathy, myocardial infarction and fibrosis .
    B7-33
  • HY-112205
    RR-11a
    3 Publications Verification

    		 Legumain Cancer
    RR-11a is a synthetic enzyme inhibitor of Legumain (IC50=31-55 nM). RR-11a can be used for the research of cancer and acute myocardial infarction (AMI) .
    RR-11a
  • HY-103185
    CCPA
    1 Publications Verification

    2-Chloro-N6-cyclopentyladenosine

    		 Adenosine Receptor Adenylate Cyclase Cardiovascular Disease Neurological Disease
    CCPA (2-Chloro-N6-cyclopentyladenosine) a highly selective A1 adenosine receptors agonist with a Ki of 0.4 nM. CCPA inhibits adenylate cyclase with an IC50 of 33 nM. CCPA exhibits anti-seizure and cardiacprotective activity. CCPA can be used for the research of seizure and myocardial infarction .
    CCPA
  • HY-17494
    Timolol

    (S)-L-714,465; MK 950 free base

    		 Adrenergic Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect .
    Timolol
  • HY-P6437A
    Drp1 peptide inhibitor P110 TFA

    		Dynamin Cardiovascular Disease Neurological Disease
    Drp1 peptide inhibitor P110 (Compound P110) TFA is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 TFA can inhibit the activation of Drp1, prevent MPTP (HY-15608)-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 TFA can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .
    Drp1 peptide inhibitor P110 TFA
  • HY-B0384
    Temocapril hydrochloride
    2 Publications Verification

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Temocapril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
    Temocapril hydrochloride
  • HY-P3436
    WLSEAGPVVTVRALRGTGSW

    		Exosomes Cardiovascular Disease
    WLSEAGPVVTVRALRGTGSW is a cardiomyocyte-targeting peptide that specifically recognizes tenascin X on the surface of cardiomyocytes. WLSEAGPVVTVRALRGTGSW can serve as a targeting ligand to conjugate with various therapeutic carriers (drugs, genes, exosomes, nanoparticles, etc.) for research on cardiovascular diseases (such as myocardial infarction, heart failure) .
    WLSEAGPVVTVRALRGTGSW
  • HY-N6020B
    Butin
    1 Publications Verification

    		 Others Cardiovascular Disease Inflammation/Immunology
    Butin is a major biologically active flavonoid isolated from the heartwood of Dalbergia odorifera with oral activity, with strong antioxidant, antiplatelet and anti-inflammatory activities. Butin significantly alleviates myocardial infarction and improves heart function, together with prevents diabetes-induced cardiac oxidative damage in rat .
    Butin
  • HY-100408
    GNF-6231

    		Wnt Porcupine Cardiovascular Disease Cancer
    GNF-6231 is a porcupine (IC50= 0.8 nM), Pron, and endoplasmic reticulum protein inhibitor with oral activity. GNF-6231 has anticancer activity. GNF-6231 can prevent the activation of the Wnt pathway by blocking the secretion of all Wnt ligands. GNF-6231 can be used in the study of myocardial infarction .
    GNF-6231
  • HY-176716
    ALDH2 activator 1

    		Aldehyde Dehydrogenase (ALDH) Cardiovascular Disease
    ALDH2 activator 1 (Compound Z17) is an allosteric aldehyde dehydrogenase 2 (ALDH2) agonist. ALDH2 activator 1 enhances cardiac function and reduces myocardial necrosis in a mouse model of myocardial ischemia-reperfusion. ALDH2 activator 1 is promising for research of cardiovascular diseases such as myocardial infarction (MI) .
    ALDH2 activator 1
  • HY-119350B
    Zalunfiban dihydrochloride

    RUC-4 dihydrochloride

    		 Integrin Cardiovascular Disease
    Zalunfiban (RUC-4) dihydrochloride is a potent, selective platelet αIIbβ3 antagonist (IC50=45 nM). Zalunfiban dihydrochloride can be used for the research of myocardial infarction (MI) .
    Zalunfiban dihydrochloride
  • HY-100713
    Temocapril
    2 Publications Verification

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
    Temocapril
  • HY-106262B
    Delcasertib hydrochloride
    3 Publications Verification

    KAI-9803 hydrochloride; BMS-875944 hydrochloride

    		 PKC Cardiovascular Disease Inflammation/Immunology
    Delcasertib (KAI-9803) hydrochloride is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) hydrochloride could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI) .
    Delcasertib hydrochloride
  • HY-123422
    GSK360A

    		HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    GSK360A is a potent and orally active HIF-PHD inhibitor with IC50 values of 10, 100, and 126 nM for PHD1, PHD2, and PHD3, respectively. GSK360A activates the HIF-1 alpha pathway and protect the failing heart after myocardial infarction (MI) .
    GSK360A
  • HY-107335
    Aplodan

    Creatinol O-phosphate; Creatinol phosphate; Creatinolfosfate

    		 Biochemical Assay Reagents Cardiovascular Disease
    Aplodan (Creatinol O-phosphate) is an antiischemic and antiarrhythmic agent. Aplodan has a protective action on cell membrane. Aplodan has the potential for the research of ischemic heart or acute myocardial infarction .
    Aplodan
  • HY-106262
    Delcasertib

    KAI-9803; BMS-875944

    		 PKC Cardiovascular Disease Inflammation/Immunology
    Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI) .
    Delcasertib
  • HY-153999
    Rondaptivon pegol

    BT200

    		 Integrin Apoptosis Cardiovascular Disease Inflammation/Immunology
    Rondaptivon pegol (BT200) is an aptamer targeting von Willebrand factor (VWF), with an EC50 of 33 nM in humans. Rondaptivon pegol effectively alleviates acute myocardial ischemia-reperfusion injury in mice by inhibiting VWF activity, reducing microvascular obstruction, inflammatory responses and cardiomyocyte apoptosis (apoptosis). Rondaptivon pegol inhibits the binding of VWF to platelet glycoprotein GPIb, thereby preventing arterial thrombosis in cynomolgus monkeys. Rondaptivon pegol can be used in research related to arterial thrombosis, stroke, myocardial infarction and myocardial ischemia-reperfusion injury .
    Rondaptivon pegol
  • HY-P99891
    Rovelizumab
    1 Publications Verification

    Hu23F2G

    		 Integrin Cardiovascular Disease
    Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke .
    Rovelizumab
  • HY-125972
    zr17-2

    		Keap1-Nrf2 Heme Oxygenase (HO) Cardiovascular Disease Neurological Disease
    zr17-2 is a cold inducible RNA-binding protein (CIRBP) agonist. zr17-2 has anti-inflammatory and anti-oxidant and can be used for the study of myocardial infarction. zr17-2 is a hypothermia mimetic molecule that reduces oxidative stress-induced retinal cell death .
    zr17-2
  • HY-12184
    ONO-AE 248

    		Prostaglandin Receptor Endogenous Metabolite Cardiovascular Disease
    ONO-AE 248 is a selective EP3 receptor agonist with cardioprotective activity. ONO-AE 248 reduces myocardial infarction size by selectively binding to the EP3α receptor in mice. The cardioprotective effect of ONO-AE 248 is independent of hemodynamic effects. The mechanism of ONO-AE 248 may involve activation of protein kinase C and opening of K(ATP) channels .
    ONO-AE 248
  • HY-P4911A
    SDF-1α (human) TFA
    2 Publications Verification

    		 CXCR Cardiovascular Disease
    SDF-1α (human) TFA is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) TFA can be used in cardiovascular disease research .
    SDF-1α (human) TFA
  • HY-17380R
    (S)-Timolol maleate (Standard)

    (S)-L-714,465 maleate (Standard); MK 950 (Standard)

    		 Reference Standards Adrenergic Receptor Cardiovascular Disease Neurological Disease
    (S)-Timolol (maleate) (Standard) is the analytical standard of (S)-Timolol (maleate). This product is intended for research and analytical applications. (S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic β-adrenoceptor blocker. (S)-Timolol Maleate is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor. (S)-Timolol Maleate can be used for hypertension, angina pectoris and myocardial infarction .
    (S)-Timolol maleate (Standard)
  • HY-150682
    FXIa-IN-9

    		Factor Xa Cardiovascular Disease
    FXIa-IN-9 (compound 3f) is a potent and selective FXIa inhibitor. FXIa-IN-9 can bind with FXIa and form hydrogen bond (human FXIa Ki: 0.17 nM, rabbit FXIa Ki: 0.5 nM). FXIa-IN-9 also has anticoagulant activity, and can be used in the research of thromboembolic diseases such as atrial fibrillation, stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism .
    FXIa-IN-9
  • HY-117970
    MMPI-1154

    		MMP Cardiovascular Disease
    MMPI-1154 is a promising novel cardio-cytoprotective imidazole-carboxylic acid (ICA) MMP-2 inhibitor(IC50=6.6 μM) and can be used for the study of acute myocardial infarction. MMPI-1154 also inhibits the activity of MMP-13, MMP-1 and MMP-9 with IC50s of 1.8 μM,10 μM, and 13 μM, respectively .
    MMPI-1154
  • HY-N11222
    Nonanoylcarnitine

    C9 carnitine

    		 Endogenous Metabolite Cardiovascular Disease Cancer
    Nonanoylcarnitine is a metabolite associated with chronic environmental exposure to polycyclic aromatic hydrocarbons (PAH) and fragmented QRS waves in acute myocardial infarction. Nonanoylcarnitine can be used as a potential biomarker for the metabolic outcome of PAH exposure and the prognosis of acute myocardial infarction .
    Nonanoylcarnitine
  • HY-P99645
    Goflikicept

    RPH 104

    		 Interleukin Related Cardiovascular Disease Inflammation/Immunology
    Goflikicept (RPH 104) is a fusion protein that selectively binds and inactivates both circulating IL-1β and IL-1α. Goflikicept has the potential for the research of ST-segment elevation myocardial infarction (STEMI) .
    Goflikicept
  • HY-P4911
    SDF-1α (human)

    		CXCR Cardiovascular Disease
    SDF-1α (human) is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) can be used in cardiovascular disease research .
    SDF-1α (human)
  • HY-129953A
    5-trans Prostaglandin F2α

    5-trans PGF2α

    		 Endogenous Metabolite Cardiovascular Disease
    5-trans Prostaglandin F2α is an endogenous metabolite present in Blood that can be used for the research of Myocardial Infarction .
    5-trans Prostaglandin F2α
  • HY-119350
    Zalunfiban

    RUC-4

    		 Integrin Cardiovascular Disease
    Zalunfiban (RUC-4) is a potent, selective platelet αIIbβ3 antagonist (IC50=45 nM). Zalunfiban can be used for the research of myocardial infarction (MI) .
    Zalunfiban
  • HY-B1409S
    Isosorbide dinitrate-13C6

    ISDN-13C6

    		 NO Synthase Cardiovascular Disease
    Isosorbide dinitrate- 13C6 is the 13C labeled Isosorbide dinitrate . Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI) .
    Isosorbide dinitrate-13C6
  • HY-142059
    PDE5-IN-4

    		Phosphodiesterase (PDE) Cardiovascular Disease Metabolic Disease
    PDE5-IN-4 is a phosphodiesterase 5 inhibitor. PDE5-IN-4 can be used for the research of acute myocardial infarction and damage caused by reperfusion, gastrointestinal diseases, damage caused by diabetes, and liver failure .
    PDE5-IN-4
  • HY-19463A
    F15845

    		Sodium Channel Cardiovascular Disease
    F 15845 is a highly effective persistent sodium current blocker. F 15845 also is a cardioprotective agent, has anti-ischemic activity and exerts short- and long-term cardioprotection after myocardial infarction. F 15845 can be used for the research of myocardium functional impairment .
    F15845
  • HY-19463
    F-15845 hydrobromide

    		Sodium Channel Cardiovascular Disease
    F 15845 hydrobromide is a highly effective persistent sodium current blocker. F 15845 hydrobromide is also a cardioprotective agent, has anti-ischemic activity and exerts short- and long-term cardioprotection after myocardial infarction. F 15845 hydrobromide can be used for the research of myocardium functional impairment .
    F-15845 hydrobromide
  • HY-134418R
    NOTA (Standard)

    		Radionuclide-Drug Conjugates (RDCs) Reference Standards Cardiovascular Disease Cancer
    NOTA (Standard) is the analytical standard of NOTA. This product is intended for research and analytical applications. NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools. NOTA also can be used for probe design and signal amplification via the multivalent effect. NOTA can be used in multiple myeloma, breast cancer, lymphoma and myocardial infarction research .
    NOTA (Standard)
  • HY-106994A
    Nebentan potassium

    YM598

    		 Endothelin Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Nebentan potassium (YM598) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan potassium inhibits [ 125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively . YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo .
    Nebentan potassium
  • HY-112079
    NPC-15669

    		Integrin Cardiovascular Disease
    NPC-15669 is a novel Mac-1 inhibitor. NPC-15669 reduces plasma levels of ET-1, TxB, prostacyclin, AT-III, and total protein S. NPC-15669 can be used in the research of myocardial infarction .
    NPC-15669
  • HY-P99886
    Pexelizumab

    h5G1. 1-SC

    		 Complement System Apoptosis Cardiovascular Disease Neurological Disease
    Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction .
    Pexelizumab
  • HY-175675
    P2Y1 antagonist 4

    		P2Y Receptor Keap1-Nrf2 Cardiovascular Disease Neurological Disease
    P2Y1 antagonist 4 is a selective P2Y1 receptor antagonist with excellent blood-brain barrier (BBB) penetration. P2Y1 antagonist 4 inhibits P2Y1 receptor-mediated cytosolic Ca 2+ increase (IC50 = 1.95 μM) and platelet aggregation (IC50 = 3.24 μM) induced by ADP in rabbit washed platelets. P2Y1 antagonist 4 significantly upregulates the level of nuclear Nrf2 protein in H2O2-treated HT22 cells. P2Y1 antagonist 4 reduces myocardial infarct size in a mouse acute myocardial infarction (MI) model. P2Y1 antagonist 4 can be used for the study of ischemic stroke and myocardial infarction .
    P2Y1 antagonist 4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: